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ABSTRACT
The S100 calcium-binding protein A4 (S100A4) induces epithelial mesenchymal 
transition, migration, invasion, angiogenesis and metastasis. Its induced expression 
in several cancer types correlates with poor prognosis. Apart from the functional and 
transcriptional regulatory aspects of S100A4, its post-transcriptional regulation is 
not yet clearly elucidated. In this study, we show that microRNAs (miR) miR-505-5p  
and miR-520c-3p target the 3′-UTR of S100A4 and inhibits its expression and its 
mediated migration and invasion. 5-Aza treatment significantly increased miR-520c-3p 
expression and reduced the S100A4 protein amounts. The upstream promoter region of 
miR-520c is hypermethylated irrespective of the metastasis status of colorectal cancer 
(CRC) patient tissues and in all analyzed CRC cell lines. Moreover, in a cohort of CRC 
patient specimen (n = 59), miR-520c-3p was significantly downregulated. miR-520c-3p  
stably expressing HCT116 cells showed a reduced metastasis formation in livers after 
implanting in mice spleen. Taken together, our findings demonstrate that S100A4 is post-
transcriptionally regulated by tumor suppressor miRs, miR-505c-5p and miR-520c-3p,  
and particularly miR-520c-3p expression is epigenetically silenced in CRC. 
INTRODUCTION
Among the different cancer entities, colorectal 
cancer (CRC) is one of the most common cancers in both 
men and women worldwide. According to estimations, 
cancer cases worldwide might raise to 24 million by 2035 
from 14 million as projected in 2012. This huge increase 
in new cases is a challenge for both governments and 
health organisations, which can be better handled with 
early detection and better treatment methods [1, 2]. Early 
detection of disease is a tough and laborious process 
due to the heterogeneity in the causes of cancer, both 
genetically and environmentally. One approach to address 
this is the search for novel tumor markers and the study of 
their regulation and molecular function [3, 4]. One such 
molecule is S100 calcium-binding protein A4 (S100A4), 
which has been identified as a prognostic biomarker in a 
variety of solid cancers [5, 6]. 
S100A4 is a calcium binding protein with the mass 
of 10–12 kDa and belongs to the family of S100 proteins, 
which consists of 21 members [7, 8]. S100A4 expression 
is transcriptionally regulated by β‑catenin and both were 
found to be highly expressed at the invasive margin of a 
tumor [9–11]. β‑catenin is a downstream effector molecule 
of the Wnt signaling axis. This pathway is deregulated 
in different cancers, including CRC, due to the loss of 
function of the β‑catenin destruction complex or gain of 
function of β‑catenin itself [12, 13]. S100A4 is known for 
its ability to activate several signaling cascades, like the 
receptor for advanced glycation end products (RAGE) 
signaling, mitogen-activated protein (MAP) kinases, 
and activated nuclear factor kappa-light-chain-enhancer 
of activated B cells (NFκB) [14]. Moreover S100A4 
increases the secretion of matrix metalloproteinases 
(MMP) such as MMP9 and MMP13 [15, 16]. Epithelial-
mesenchymal transition (EMT) is one of the key switch 
events in cancer progression. S100A4 plays an important 
role in inducing proliferation, EMT, migration, invasion 
and colony formation [6, 17]. S100A4 binds to cytoskeletal 
proteins like myosin-IIA and negatively regulates the 
polymerization of its filaments. Under hypoxia conditions 
S100A4 activates the ERK signaling axis [14, 18]. S100A4 
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induces cell migration by disrupting molecular functions 
of the two molecules myosin-IIA and ERK.
Apart from β‑catenin, S100A4 is transcriptionally 
regulated by SP1, AP1 and kappa recognition component 
(KRC) transcription factors and further it is controlled by 
CpG island methylation [19, 20]. S100A4 is overexpressed 
in a variety of cancer entities like CRC, non-small cell 
lung, breast, oesophageal, gastric and hepatocellular 
cancers. Moreover, its induced expression is positively 
correlated with tumor progression, metastasis and poor 
survival of patients [6, 21]. However, to our knowledge 
only miR-187-3p is reported to post-transcriptionally 
regulate S100A4 and S100A4 mediated metastasis [22]. 
This was so far only shown in hepatocellular carcinoma 
(HCC). However, there is no data about S100A4 post-
transcriptional regulation by microRNAs (miRs), which 
might be down regulated due epigenetic silencing in CRC.
miRs are a class of small RNAs with lengths around 
22 nucleotides (nt), which are expressed in a cell and 
tissue‑specific manner. These molecules regulate mRNA 
stability and protein translation. miRs control a wide 
range of biological functions such as cellular proliferation, 
differentiation, apoptosis, EMT, migration, invasion, 
metastasis, drug resistance, epigenetic machinery and 
are also known as diagnostic and prognostic markers 
[23–25]. Especially, an upregulation of miR-21, and of 
the miR-29 family, as well as a downregulation of the 
miR-34 family and of miR-124a in tumor specimens 
are considered as prognostic markers in CRC [25–28]. 
DNA hypermethylation is one of the main reasons for 
the downregulation of the miR-34a family and miR-
124a in cancer specimens [29, 30]. A change of the miR 
expression leads to a deregulation of their respective target 
proteins, which correlates with cancer progression.  
All this evidence prompted us to design a 
comprehensive study on the post-transcriptional regulation 
of S100A4 by miRs and the epigenetic regulation of these 
miRs in CRC.
RESULTS 
The S100A4-3′-UTR is a target of miR-505-5p 
and miR-520c-3p
The 140 nt‑3′UTR of S100A4 (#NM_019554.2) 
was screened for complementary seed sequences of 
miRs using in silico approaches (miRWalk, RNAhybrid). 
Complementary target sequences were identified for 
miR-505-5p at nt 77–85, and for miR-520c-3p at nt 59–65 
(Figure 1A). The minimum free energy predicted for 
hybridization of miR-505-5p or miR-520c-3p with the 
S100A4‑3′‑UTR at their site is ΔG = –26.2 kcal/mol and 
ΔG = –24.5 kcal/mol, respectively, determined by mFold 
analysis (Supplementary Figure 1A, 1B). 
Given the results from the in silico analyses, 
we hypothesized that the S100A4‑3′‑UTR could be a 
functional target of miR-505-5p and miR-520c-3p. To 
address this question, we cloned 164 nt of the 3′‑UTR of 
S100A4, including 28 nt of the upstream coding sequence, 
in a pmirGLO dual‑luciferase vector at the 3′‑position of a 
luciferase reporter gene (S100A4‑3′‑UTR). The S100A4‑
3′‑UTR was co‑transfected along with control‑miR, miR 
mimics or inhibitors (anti-miRs) of miR-505-5p and 
miR-520c-3p in HCT116 and SW620 cells. The luciferase 
activity of cells transfected with mimics together with 
S100A4‑3′‑UTR was significantly reduced compared 
to control-miR (HCT116 cells miR-505-5p (p = 0.02), 
miR-520c-3p (p = 0.01); SW620 cells miR-505-5p 
(p = 0.0009), miR-520c-3p (p = 0.003). On the other hand, 
cells that were transfected with the anti-miR inhibitor 
along with the S100A4‑3′‑UTR showed a significantly 
induced luciferase activity compared to the respective 
control (HCT116 cells anti-miR-505-5p (p = 0.01), anti-
miR-520c-3p (p = 0.003); SW620 cells anti-miR-505-5p 
(p = 0.02), anti-miR-520c-3p (p = 0.005) Figure 1B). 
Similarly, co-transfections with constructs of S100A4-
3′‑UTR harboring the mutated seed sequences of either 
miR-505-5p or miR-520c-3p and the respective miRs did 
not significantly reduce the luciferase activity compared 
to the control-miR condition. Taken together, these data 
suggest that the 3′‑UTR of S100A4 is a direct functional 
target of miR-505-5p and miR-520c-3p. 
miR-505-5p and miR-520c-3p regulate the 
S100A4 gene expression
To support the reporter assay results, HCT116 and 
SW620 cells were transfected with control-miR, miR 
mimics or anti-miRs of miR-505-5p and miR-520c-3p. 
The mRNA and protein expression analyses showed 
that miR-505-5p and miR-520c-3p reduced the S100A4-
transcript levels in HCT116 (p = 0.01 and p = 0.01) and 
SW620 cells (p = 0.01 and p = 0.02), but no significant 
changes were observed in the anti-miR-505-5p and anti-
miR-520c-3p conditions compared to the control-miR 
(Figure 1C). Western blotting confirmed the significant 
downregulation of S100A4 protein amounts in both cell 
lines, HCT116 and SW620, transfected with miR-505-5p 
(p = 0.01 and p = 0.04) and miR-520c-3p (p = 0.03 and 
p = 0.05). Moreover, transfection of anti-miR-505-5p and 
anti-miR-520c-3p slightly induced protein expression 
of S100A4 compared to the control-miR (Figure 1D, 
Supplementary Figure 5B). Taken together, these results 
suggest that S100A4 is post-transcriptionally regulated 
by miR-505-5p and miR-520c-3p through binding to its 
3′‑UTR in CRC cell lines.
miR-505-5p and miR-520c-3p inhibit the 
S100A4-mediated migration and invasion 
To further investigate the functional abilities of 
miR-505-5p and miR-520c-3p in mediating migration and 
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invasion, we transfected HCT116 and SW620 cells with 
these two miRs separately. Migration (without matrigel) 
and invasion (with matrigel) assays were performed with 
Boyden chamber transwells. Ectopic overexpression of 
miR‑505‑5p and miR‑520c‑3p significantly reduced the 
migration (p = 0.01 and p = 0.05) and invasion (p = 0.01 
and p = 0.02) in HCT116 as well as migration (p = 0.05 
and p = 0.05) and invasion (p = 0.01 and p = 0.01) in 
SW620 cells (Figure 2A, 2B). In addition, we also 
showed the S100A4 specific effects by overexpression of 
S100A4 in combination with control-miR, miR-505-5p 
or miR-520c-3p, compared to the respective vector 
controls in HCT116 cells. Ectopic S100A4 expression 
significantly increased the migration and invasion in 
HCT116 cells compared to the vector control (p = 0.029 
and p = 0.05; Figure 2A). S100A4 overexpression 
in combination with miR-505-5p or miR-520c-3p 
significantly increased migration (p = 0.006 and p = 0.02) 
and invasion (p = 0.006 and p = 0.03) of HCT116 cells 
compared to the miR overexpression in vector control 
cells, respectively. Additionally, we overexpressed 
miR-505-5p, miR-520c-3p or control-miR along with 
either si-RNA-S100A4 or si-RNA-control in SW620 cells. 
S100A4 knock‑down significantly reduced the migration 
(p = 0.008) and invasion (p < 0.001) of SW620 cells 
compared to the respective control-siRNA (Figure 2B). 
Co-transfection of miR-505-5p or miR-520c-3p along 
with si‑RNA‑S100A4 significantly reduced migration 
(p = 0.001 and p = 0.04) and invasion (p = 0.05 and 
p = 0.007) compared to the miRs overexpression in the si-
RNA‑control cells (Figure 2B). Transfection efficiency of 
miR-505-5p or miR-520c-3p was determined by qRT-PCR 
(Supplementary Figure 1B, 1C). Ectopic overexpression 
or know-down of S100A4 and the impact of miRs on 
its mRNA and protein expression levels were analyzed 
by qRT-PCR and Western blot analysis, respectively 
(Figure 2C–2F). The endogenous expression of miR-505-5p 
and miR-520c-3p was lower in SW620 compared to 
HCT116 cells, whereas the S100A4 expression was higher 
(Supplementary Figure 3A; Supplementary Figure 2A, 2B; 
Supplementary Figure 4A). Therefore, HCT116 cells 
were transfected with anti-miR-505-5p, anti-miR-520c-3p 
Figure 1: miR-505-5p and miR-520c-3p target the S100A4-3′UTR, and downregulate S100A4 expression. (A) The seed 
sequences for miR‑505‑5p and miR‑520c‑3p in S100A4‑3′‑UTR (wild type) were detected by in silico predictions. The wild type and 
mutated seed sequence were cloned into the dual-luciferase vector and luciferase assays were performed to show direct regulation of 
the S100A4‑3′‑UTR by these miRs. (B) Luciferase reporter assays of HCT116 and SW620 cells transfected with control-miR (Control), 
miR‑505‑5p, anti‑miR‑505‑5p, miR‑520c‑3p, anti‑miR‑520c‑3p and co‑transfected with either S100A4‑3′‑UTR wild type or the mutated 
constructs were performed. Renilla luciferase values of the vector were used for normalization. Percent luciferase activity was calculated 
based on the control values. (C) S100A4 mRNA expression was quantified using qRT‑PCR and RPII was used as internal control. 
(D) S100A4 Western blotting was performed and bands were densitometrically quantified by normalizing to the internal control β‑actin. 
Mean values of triplicates were represented. (*p < 0.05; **p < 0.01).
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and control-miR. Inhibition of the miRs led to increased 
S100A4 protein levels and induction of wound healing 
compared to the control-miR (Supplementary Figure 5).
Taken together, these results suggest that miR-505-5p 
and miR‑520c‑3p significantly inhibit S100A4‑mediated 
migration and invasion in CRC cells. 
5-Azacytidine treatment restores miR-520c-3p 
and inhibits the expression of S100A4  
In order to explore further insights in the network of 
miR-505-5p and miR-520c-3p and their functional effects 
on S100A4 expression, we analyzed their epigenetic 
regulation. First, we determined their endogenous 
expression in a panel of CRC cell lines (Supplementary 
Figure 3A, Supplementary Figure 4A). The miRs were 
both expressed on a relatively low level (in comparison 
with other screened miRs, under similar conditions (data 
not shown)). miR-505 is located on chromosome Xq27.1 
[–] as an intragenic miR of ATPase, Class VI, Type 11C 
(ATP11C) and may be expressed under the same promoter 
as its host gene. miR-520c is located on 19q13.42 [+] being 
part of a cluster of 46 miRs also known as chromosome 
19 miRNA cluster (C19MC) [31]. The ATP11C and 
miR-505-5p expression were positively correlated in CRC 
cell lines (R2 =0.84, p = 0.05, Supplementary Figure 4B). 
Especially the miR-505-5p expression was higher in 
the noninvasive cell lines, Colo206f and Colo320DM, 
Figure 2: miR-505-5p and miR-520c-3p inhibit the S100A4 mediated migration and invasion in vitro. (A) HCT116 cells 
were co-transfected with control-miR, miR-505-5p and miR-520c-3p along with either vector-control or -S100A4, respectively. After 
48 h cells were plated on top of the Boyden chambers for migration and matrigel-coated Boyden chambers for invasion. After 16 h the 
migrated or invaded cells were measured as described in the materials and methods. (B) SW620 cells were co-transfected with control-miR, 
miR-505-5p and miR-520c-3p along with either si-RNA-control (si-control) or si-RNA-S100A4 (si-S100A4), respectively. After 48 h the 
cells were used for migration and invasion assay as stated above. (C, D) Transfection efficiency of ectopic overexpression and knock‑down 
of S100A4 on mRNA level was analyzed using qRT-PCR. (E, F) S100A4 protein expression after transfection was analyzed by Western 
blots. RPII was used as internal control for S100A4 mRNA expression and β‑actin for Western blotting. (*p < 0.05).
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compared to the invasive SW620 and HCT116 cell lines 
(Supplementary Figure 4A) [30, 32]. Depending on their 
genetic location, we identified putative CpG islands in their 
promoter regions using in silico approaches. Furthermore, 
we determined their promoter methylation status using 
methylation‑specific PCR (MSP) (Supplementary 
Figure 3B; Supplementary Figure 4C; Supplementary 
Figure 6A–6C). Additionally, we analyzed the host gene 
of miR-505, ATP11C in this study. The analyzed upstream 
regulatory region of miR-520c was rich in CpG islands 
having an average CG-content of more than 80%. Both, 
miR-505 and its host gene ATP11C, had no CpG-island in 
their upstream promoter region. However, several regions 
rich in individual CpG-sites were found that could be used 
for methylation studies (Supplementary Figure 6A–6C). 
Although most human promoters are associated with CpG-
islands, this might not be the case for miR-505, which 
suggests a different regulation [33].
To analyze the degree of epigenetic regulation of 
the identified regions, gDNA was isolated from a panel of 
CRC cell lines and subjected to bisulfite conversion and 
subsequently MSP was performed with a specific set of 
“methylated” and “unmethylated” primers. The miR-505 
upstream region was unmethylated, whereas the ATP11C 
upstream region was mostly methylated (Supplementary 
Figure 4C). Moreover, the miR-520c upstream regulatory 
region was completely hypermethylated in this cell 
line panel (Supplementary Figure 3B; Supplementary 
Figure 4C). Secondly, to functionally prove these MSP 
results, we have used the DNA-methyltransferase inhibitor 
5-azacytidine (5-Aza). The treatment with 5-Aza had no 
significant impact on the expression level of miR‑505‑5p 
(Supplementary Figure 6D) in HCT116 and SW620 cell 
lines. Due to this limitation, we excluded miR-505-5p for 
further investigations.
On the other hand, the miR-520c-3p promoter was 
hypermethylated in all analyzed cell lines and its expression 
was significantly upregulated by treatment with 5‑Aza 
in SW480 (p = 0.02), SW620 (p = 0.01) and HCT116 
(p = 0.01) cells (Figure 3A). Moreover, the expression 
of its target gene S100A4 was downregulated at mRNA 
and protein level after 5-Aza treatment (Figure 3A, 3B). 
Secondly, the luciferase activity of S100A4‑3′‑UTR was 
significantly reduced upon 5‑Aza treatment in SW620 
(p = 0.001) and HCT116 (p < 0.001) cells (Figure 3C). 
Taken together, these results suggest that a restoration of 
miR‑520c‑3p could significantly inhibit the expression of 
S100A4.
Combined bisulfite restriction analysis (COBRA) 
confirms hypermethylation of miR-520c in CRC 
cell lines
To further illustrate the hypermethylation of the 
regulatory region of miR-520c, COBRA analysis was 
performed. For this assay, bisulfite converted gDNA of 
CRC cell lines was amplified by non‑methylation specific 
PCR and then digested with the restriction enzyme BstUI. 
The enzyme recognizes specifically CpG‑sites that were 
not modified by the bisulfite treatment and therefore were 
methylated before. The PCR of the miR-520c regulatory 
element created a 152 bp amplicon. BstUI cuts the PCR 
product in a 67 bp and an 85 bp fragment, which was 
visible as a new band on an agarose gel. In most of the 
analyzed cell lines the regulatory region of miR-520c 
was methylated (Figure 4A). However, the less invasive 
cell lines Colo206f, Colo320DM and WiDr were partly 
unmethylated [30]. Comparatively, these cell lines had less 
or moderate S100A4 protein amounts compared to SW620 
cells (Supplementary Figure 2B). To have additional 
evidence about the methylation status of the regulatory 
region of miR-520c and S100A4 especially in these three 
cell lines, the cells were treated with 5-Aza for 3 days and 
subsequently DNA, RNA and proteins were isolated and 
investigated. COBRA analysis and bisulfite sequencing 
showed a reduced CpG-island methylation of the miR-
520c regulatory element after 5-Aza treatment in these 
three cell lines. The reduction of methylated CpGs was 
almost 10% in Colo320DM cells compared to the DMSO 
treated control cells (Figure 4B, 4C). 
Nakamura et al, reported that hypermethylation of 
the S100A4 gene promoter correlates with its activation, 
expression and also with the cell invading capacity [32]. In 
this report the authors showed that after 5-Aza treatment 
S100A4 mRNA levels were increased in the less invasive 
cell lines SW837, LoVo and DLD-1 but not in WiDr. 
However, in our study we used Colo206f, Colo320DM 
and WiDr cell lines, which also showed a relatively low 
invasive phenotype. Treatment with 5-Aza induced the 
expression of S100A4 (except in Colo320DM) and its 
post-transcriptional regulator miR-520c-3p, which was 
determined by qRT-PCR (Figure 4D). Further, a clear 
reduction of S100A4 protein expression was observed 
in Colo320DM and WiDr cells compared to the DMSO 
condition, but no S100A4 protein was detectable in 
Colo206f cells (Figure 4E). This confirmatory analysis 
suggests that epigenetic silencing of miR-520c-3p is an 
important mechanism during cancer progression and could 
be one of the reasons for S100A4 upregulation in CRC 
cell lines.     
The miR-520c regulatory region is 
hypermethylated in CRC tumor specimens
In order to further determine the epigenetic regulation 
mechanisms of miR-520c in CRC patient tumors, we used 
representative tumor specimens of our cohort, which were 
either positive or negative for metachronous metastasis. 
Comparable to the CRC cell lines, the miR-520c 
regulatory region was hypermethylated irrespective to 
the metachronous metastasis status (Figure 5A). The 
miR-520c-3p expression showed a trend for downregulation 
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Figure 3: miR-520c regulatory region is hypermethylated in CRC cell lines and treatment with 5-Aza induces the 
expression of miR-520c-3p and downregulates S100A4 expression. (A, B) SW480, SW620 and HCT116 cells were treated with 
5-Aza (2 mM) for 3 days.  qRT-PCR and Western blots were performed to analyze the impact of 5-Aza treatment on miR-520c-3p and 
S100A4 expression. RNUB6, RPII and β‑actin served as internal controls. (C) HCT116 and SW620 cells transfected with the wild type 
S100A4‑3′‑UTR were treated with 5‑Aza (2 µM) for 24 h and the luciferase activity was measured. Renilla luciferase activity was used for 
normalization. Percentage luciferase activity was significantly reduced after 5‑Aza. (*p < 0.05).
Figure 4: COBRA and bisulfite sequencing analysis of miR-520c regulatory region. (A, B) COBRA analysis using the 
restriction enzyme BstUI was performed to estimate the methylation status of miR‑520c‑3p in CRC cell lines.  Colo206f, Colo320DM 
and WiDr were also analyzed after 5‑Aza (2 µm) treatment for 3 days. (C) Colo320DM cells were treated with 2 μM 5‑Aza for 3 days and 
the methylation of miR‑520c‑3p was analyzed by bisulfite sequencing. From each group 10 representative clones were sequenced. Each 
circle represents CpG islands in the sequenced region, and the black circle represents the methylated and the empty white circle represents 
unmethylated CpG island. (D, E) qRT-PCR of miR-520c-3p, S100A4 and Western blot analysis of S100A4 were performed after 5-Aza 
treatment of Colo206f, Colo320DM for 3 days (20 μg of total protein used for Western blot) and WiDr (5 μg of total protein used for 
Western blot) cell lines (from low to moderate S100A4 expressing cells). RNUB6, RPII and β‑actin served as internal controls. (*p < 0.05; 
**p < 0.01).
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in specimens derived from metachronous metastasis 
positive tumors compared to metachronous metastasis 
negative tumor specimens (Figure 5B). Moreover, in a 
cohort of 59 CRC patient tumor specimens miR-520c-3p 
was significantly downregulated (p = 0.003) compared 
to the normal mucosa tissues and its target S100A4 was 
significantly upregulated (p = 0.018, Figure 5C, 5D). Taken 
together, these methylation analysis and gene expression 
studies revealed that due to epigenetic downregulation of 
miR-520c-3p its post-transcriptional target S100A4 was 
upregulated in CRC tumor specimens.
miR-520c-3p inhibits metastasis formation in 
mice 
To further investigate the in vivo relevance of 
miR-520c-3p, HCT116 cells stably transduced with either 
miR‑520c‑3p (HCT116‑LUC‑miR‑520c‑3p) or control‑
miR (HCT116‑LUC‑Control) were intrasplenically 
injected in SCID beige mice. Before intrasplenic injection, 
the stable expression of miR-520c-3p and downregulation 
of its target S100A4 were analyzed by qRT-PCR and 
Western blot (Figure 6A). The mice were monitored by 
bioluminescence once per week and a similar procedure 
was performed before the termination of the experiment. 
Mice injected with HCT116 cells stably overexpressing 
miR‑520c‑3p (HCT116‑LUC‑miR‑520c‑3p) (p = 0.009; 
Figure 6B) showed slightly reduced amounts of human 
microsatellite DNA (HMD) in their liver tissue compared 
to the control group (HCT116‑LUC‑Control) (Figure 6C) 
and also we observed less metastatic lesions in the miR-
520c-3p expressing group (Figure 6D). However, these 
differences were not statistically significant due to the less 
number of sample size. 
Collectively, these data show that migration, 
invasion, and metastasis formation in vivo are inhibited 
by miR-520c-3p overexpression. 
DISCUSSION
Here we investigated the post-transcriptional 
regulation of the important metastasis-associated gene 
S100A4 by miRs and their epigenetic regulation in CRC. 
In this study, we identified two miRs, miR‑505‑5p and 
miR-520c-3p, which post-transcriptionally inhibit the 
expression of S100A4, thereby hindering its mediated 
migration, invasion and formation of distant metastasis 
of CRC cells [34]. Moreover, especially the expression of 
miR-520c-3p was downregulated in CRC cell lines and 
tumor specimens, which is partially caused by epigenetic 
silencing of the regulatory region of miR-520c-3p. 
Furthermore, our study extends the existing knowledge 
about epigenetic regulation of  S100A4 by promoter 
hypermethylation in CRC cell lines [32]. 
In this study, by in silico analyses we have identified 
miR-505-5p and miR-520c-3p as potential candidates 
targeting the 3′UTR of S100A4. By co‑transfecting miR 
mimics together with the S100A4‑3′‑UTR harboring 
Figure 5: Methylation status of the miR-520c regulatory region and expression of miR-520c-3p and its target S100A4 
in a cohort of CRC tumor specimens. (A) Methylation specific PCR products of metachronous metastasis positive and metachronous 
negative CRC tumor specimens were analyzed using agarose gel electrophoresis. The miR-520c regulatory element was methylated in all 
specimens. The two cell lines SW620 and Colo206f served as internal controls. (B) miR-520c-3p expression in metachronous metastasis 
positive (n = 10) and negative (n = 10) CRC tumor specimens in comparison to representative normal mucosa were quantified using 
qRT-PCR. (C, D) miR-520c-3p and S100A4 expression in CRC tumor specimens in comparison to representative normal mucosa were 
quantified using qRT‑PCR. RPII and RNUB6 served as internal controls. 
Oncotarget21088www.impactjournals.com/oncotarget
either the wild type or mutated seed sequences of the 
predicted miRs, we identified S100A4 as a novel target 
of miR-505-5p and miR-520c-3p. Moreover, ectopic 
expression of miR-505-5p or miR-520c-3p decreased 
S100A4 mRNA and protein expression, whereas inhibition 
of the endogenous miRs by anti-miRs increased S100A4 
expression. Further, loss or gain of function of miR-505-
5p and miR-520c-3p along with S100A4 overexpression 
or knock-down clearly demonstrated that they mitigate the 
S100A4 mediated migration and invasion [35–37]. In the 
majority of CRC tumor specimens Wnt signalling is known 
to be dysregulated and therefore constitutively active, 
whereas S100A4 is a downstream effector molecule of 
this signalling [9, 34]. Secondly, loss of epigenetic control 
leads to increased expression of S100A4, which was 
shown to be a prognostic marker for poor survival of CRC 
patients [5, 38]. Beside the reports about its transcriptional 
regulation the post-transcriptional regulation of S100A4 
is not well understood. miR-187-3p is reported to post-
transcriptionally regulate S100A4 and S100A4-mediated 
metastasis in  hepatocellular carcinoma (HCC) [22]. Here 
we demonstrate that loss of post-transcriptional regulation 
of S100A4 due to epigenetic silencing of miR-505-5p and 
miR-520c-3p expression could be one of the main causes 
for the induction of S100A4 expression in CRC and other 
cancer entities.
Epigenetic regulation of gene activity plays a major 
role in cancer development and disease progression [39]. 
Canonical DNA methylation occurs mainly within the 
context of CpG-dinucleotides that are organized in bigger 
regions termed islands or shores [40]. It is already an 
established mechanism during the embryonal period in a 
tissue specific manner [41]. The DNA methyltransferase 
1 (Dnmt1), Dnmt3a and Dnmt3b enzymes are required 
for the establishment and maintenance of these 
methylation patterns [42]. Loss or gain of function of 
methyltransferases result in abnormal gene regulation, 
which could lead to downregulation of tumor suppressor 
genes and upregulation of tumor promoting genes [30, 39]. 
Nakamura et al. reported for the first time that S100A4 
promoter hypermethylation leads to its downregulation in 
less aggressive colon adenocarcinoma cell lines [32]. In 
concordance with these findings, we also observed induced 
S100A4 mRNA expression after 5-Aza treatment in less 
aggressive CRC cell lines such as Colo206f, Colo320DM 
and WiDr, but not in the more aggressive cell lines SW480, 
SW620 and HCT116. However, S100A4 protein amounts 
were reduced after 5-Aza treatment in all of these cell 
lines irrespective of their invasive or aggressive nature, 
except for Colo206f  cells [30]. In comparison to the other 
screened CRC cell lines, Colo206f and Colo320DM had 
less or no endogenous expression of S100A4. In particular, 
Figure 6: Overexpression of miR-520c-3p inhibits metastasis formation in vivo. (A) HCT116 cells stably expressing 
miR‑520c‑3p or control‑miR were generated. The overexpression of the miR was quantified by qRT‑PCR and compared to control‑
miR. The expression of the target gene S100A4 in the miR overexpressing cells was downregulated as indicated by Western blotting. 
(B) The cells were intrasplenically injected in SCID beige mice and sacrificed after 20 days. The expression of miR‑520c‑3p in the shock‑
frozen primary tumor in the spleen was quantified by qRT‑PCR. (C) Metastasized cells into the liver of the animals were analyzed using 
specific primers to exclusively detect HMD by qRT‑PCR. Less amounts of HMD were detectable in the liver sections of the miR‑520c‑3p 
overexpressing group. (D) The cells were intrasplenically injected in SCID beige mice and tumor and metastasis formation was monitored 
by bioluminescence imaging. Representative mice from each group are shown on the day the animals were sacrificed. (*p < 0.05).
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Colo206f showed induced S100A4 mRNA expression after 
5-Aza treatment. However, in Western blotting even at 
higher concentrations of protein loading we didn’t observe 
any S100A4 protein band compared to the Colo320DM 
cell line. One explanation could be that S100A4 might 
be regulated in a cell line specific manner via a different 
mechanism other than discussed.   
5-Aza treatment increased the miR-520c-3p 
expression in a panel of CRC cell lines irrespective of 
their characteristics. This gives additional evidence to 
analyze the hypermethylation status of the miR-520c 
regulatory region in all CRC cell lines. COBRA and 
bisulfite sequencing analysis further confirmed that the 
miR-520c regulatory region is hypermethylated in CRC 
cell lines. This finding is in line with previously described 
epigenetic silencing of the C19MC cluster members in 
HCC and gastric cancer [43, 44]. Loss of methylation in 
its regulatory region increases the miR-520c-3p expression 
and inhibits its target gene S100A4 protein amount after 
5-Aza-treament in comparison to DMSO controls. On 
the other hand, the methylation pattern of the miR-520c 
regulatory region did not show significant differences 
in CRC tumor specimens, which were either positive or 
negative for metachronous metastasis. Interestingly, we 
have observed that the miR-520c-3p expression tend to 
be lower expressed in metachronous metastasis positive 
specimens compared to the negative specimens. These 
results suggest that besides CpG hypermethylation 
additional alternative epigenetic or transcriptional 
regulatory mechanisms might be involved in expression 
control of miR-520c-3p. Overall, in a cohort of CRC 
patient tumor specimens, a significant downregulation 
of miR-520c-3p expression and upregulation of S100A4 
mRNA expression was observed. About miR-520c-3p 
there are several reports indicating its role as tumor 
suppressor miR or oncomir depending on the cancer 
entity [45–48]. Our findings in this study strongly support 
miR-520c-3p as tumor suppressor miRNA which is 
downregulated in CRC and also causes upregulation of 
its target proteins such as the metastasis-associated gene 
S100A4 in tumor tissue [9, 37, 49]. Moreover, miR-520c-
3p belongs to the C19MC cluster and also other members 
of this cluster were reported to have a tumor suppressive 
function, which is in line with previous findings that miR 
family members can regulate similar targets and pathways 
[49–53]. To sum up, our findings highlight the key role 
of miR-520c-3p as a tumor suppressor, which is silenced 
by hypermethylation of its regulatory region in CRC. 
Loss of miR-520c-3p expression during tumorigenesis is 
in part responsible for the S100A4 upregulation in CRC. 
Our study also identified S100A4 as the first cancer‑
associated target of miR-505-5p and its functional impact 
on metastasis-associated characteristics like migration 
and invasion. miR-505-5p was so far only shown to be 
dysregulated in cancer tissue compared to normal mucosa 
but no functional evidence was reported [54, 55].
S100A4 is known for inducing proliferation, EMT, 
migration and invasion in vitro and tumor metastasis 
events in vivo [56, 57]. sh-RNA mediated knock-
down of S100A4 significantly reduced the CRC cell 
mediated metastasis formation [57]. With this line of 
evidence, we intrasplenically injected HCT116 cells 
stably overexpressing miR-520c-3p in SCID beige mice 
and observed slightly reduced metastasis formation in 
the liver compared to the control-miR group. With this 
results, one can speculate that especially in this context the 
downregulation of miR-520c-3p due to a hypermethylation 
of its regulatory region could be one of the mechanisms for 
S100A4 overexpression in different cancer entities, apart 
from its previously described epigenetic and Wnt/β‑catenin 
mediated transcriptional regulation [14, 58].
In conclusion, this study highlights a pivotal role 
of miR-505-5p and miR-520c-3p in various aspects 
of tumorigenesis such as migration, invasion, and 
in vivo metastasis formation in CRC through the post-
transcriptional regulation of their novel target S100A4. 
Additionally, we demonstrated the epigenetic silencing of 
miR-520c-3p as possible mechanism during carcinogenesis, 
which lead to upregulation of S100A4. These findings 
certainly add additional information to the S100A4 biology 
and its targeted therapeutic approaches.   
MATERIALS AND METHODS
Construction of 3′-UTR-luciferase plasmids, 
reporter assays, miRs, siRNA and plasmids
The 3′‑UTR of S100A4 (including 28 nt of the 
coding sequence and 136 nt of 3‑′UTR) was amplified 
using cDNA from SW480 cells and cloned into the 
XhoI and SalI sites of the pmirGLO dual-luciferase 
miRNA target expression vector (#E1330, Promega, 
USA), checked for orientation, sequenced and named 
S100A4‑3′‑UTR. Specific miR‑505‑5p and miR‑520c‑
3p seed sequences were mutated using PCR based site 
directed mutagenesis kit (#210518, Agilent technologies, 
USA). Cloning and site directed mutagenesis primers are 
provided in Supplementary Table 1 and 2. For reporter 
assays, cells were co-transfected using Lipofectamine 
2000 (Invitrogen, Carlsbad, USA) with 1 μg of luciferase 
construct along with 50 nM of control‑miR or mimics/
inhibitor miRs. Reporter assays were performed 48 h 
post-transfection using the dual-luciferase assay-system, 
normalized for transfection efficiency by renilla luciferase.
miRNA mimic miR-505-5p (ID: MC12497), miR-
520c-3p (ID: MC12719),  miRNA inhibitor anti-miR-505-5p 
(ID: MH12497), anti-miR-520c-3p (ID: MH12719), miR-
negative control (#4464058), siRNA targeting S100A4 
(ID:12226) and scrambled control (#4390843) were 
purchased from Ambion, USA. Lentiviral constructs 
of control‑miR (#CmiR0001‑MR03) and miR‑520c‑3p 
(#HmiR0327‑MR03) were purchased from GeneCopoeia, 
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USA. CMV promoter–controlled S100A4 cDNA and 
the empty vector as control were kind gifts from Claus 
Heizmann (University of Zurich, Switzerland). 
Cell lines, cultures and drugs
Human CRC cell lines (SW480, Rko, DLD-1, 
HCT116, SW620, HT-29, Colo320DM, WiDr, Caco-2 
and HCT-15) were purchased from American Type Culture 
Collection (ATCC; Manassas, VA), and Colo206f from 
German Collection of Microorganisms and Cell culture 
(DSMZ Leibniz Institute; Braunschweig, Germany). The 
cells were grown in a humidified incubator at 37°C and 5% 
CO2 with RPMI (Colo320DM, Colo206f, SW480, WiDr, 
HCT-15) and DMEM (rest of the cells used for this study) 
media supplemented with 10% fetal calf serum (FCS). All 
used cell lines were authenticated using genotyping and 
were mycoplasma free. Original stock solutions of 5-Aza-
2′‑deoxycytidine (5‑Aza‑dC (#A2385), Sigma Chemical 
Co., USA) at a concentration of 10 mM was stored at 
–20°C and freshly dissolved in culture medium before use. 
Virus production and generation of stably miR 
expressing cell lines 
1.5 × 107 HEK293 cells were plated for transfection. 
After 24 h cells were transfected using 2.85 ml of 
serum free medium, which was mixed with 90 µg of 
polyethylenimine (PEI) and kept at room temperature 
for 5 min. Either 30 µg of control‑miR or miR‑520c‑3p 
lentiviral plasmids (containing also GFP) with packing 
vectors (20 µg psPax2, 10 µg pMD2.G) were individually 
mixed and incubated at room temperature for 20 min. 
These mixtures were added to the respective plates. 
After 48 h of incubation, the supernatant was collected 
and filtered (0.45 µm filter). In a further step the filtered 
supernatant was loaded on a 20% sucrose cushion and 
centrifuged at 4oC for 4 h in an ultracentrifuge (28,000 
rpm). The viral particles were dissolved in 500 µl sterile 
PBS and stored at -80oC. HCT116 cells were transduced 
in 6 well plates with a multiplicity of infection (MOI) less 
than 10 for each respective well. After 24 h of incubation, 
the virus containing medium was replaced with the regular 
medium and the GFP expressing cells were sorted using 
FACS. After sorting, the miR-520-3p expression of the 
stably overexpressing HCT116 cells were analyzed 
by qRT-PCR and compared to the control-miR cells. 
In addition, control-miR and miR-520c-3p expressing 
cells were transduced with eGFP‑LUC virus. The miR‑
scrambled (HCT116‑LUC‑Control) and miR‑520c‑3p 
(HCT116‑LUC‑miR‑520c‑3p) along with luciferase‑GFP 
stably expressing cells were used for animal experiments. 
The detectable luminescence values of both cell lines were 
comparable. 
Metastasis formation in xenografted mice
Animal experiments were performed at EPO GmbH, 
Berlin, in accordance with the UKCCCR guidelines 
and approved by the responsible local authorities (State 
Office of Health and Social Affairs, Berlin, Germany). 
For analysis, 3 × 106 cells of HCT116‑LUC‑Control or 
HCT116‑LUC‑miR‑520c were transplanted into the 
spleens of 8 weeks old severe combined immunodeficiency 
(SCID) beige mice (randomly assigned to 6 mice per 
group before transplantation). The mice were imaged 
once a week in a NightOWL LB 981 system (Berthold 
Technologies, Germany) by intraperitoneal injection of 
150 mg/kg D‑luciferin (Biosynth, Switzerland) under 
temporal anesthesia with isoflurane (Sigma‑Aldrich, 
Germany). Mice were sacrificed 20 days after tumor cell 
transplantation. Spleens (site of tumor injection) and livers 
(metastasis target organ) were removed and shock-frozen 
in liquid nitrogen and cryosections were performed for 
isolation of genomic DNA (Qiagen, Hilden, Germany) and 
RNA (TRIzol, Invitrogen). The level of liver metastasis 
was evaluated by quantifying HMD using PCR with 
primers provided in Supplementary Table 3. ImageJ was 
used for color coding of luminescence signal intensity of 
human cells.  
Patients and samples
Fresh snap-frozen surgical specimens of tumor 
tissues and representative corresponding normal specimens 
from 59 CRC patients were collected with informed written 
consent (approved by Charité Ethics Committee, Charité-
Universitätsmedizin, Berlin), preserved and processed 
as explained in our previous publications [59]. The main 
patients’ characteristics are reported in Supplementary 
Table 4. None of the patients received preoperative chemo/
radiation therapy and none of the researchers conducting 
gene expression and statistical analyses had access to 
disclosed clinical-pathological data. 
DNA/RNA/Protein isolation and cDNA synthesis 
from cells and fresh snap-frozen CRC specimens
DNA, RNA and protein isolation and cDNA synthesis 
were performed as described previously by Ilm et al. 
[59]. Briefly, for isolation of DNA and RNA from frozen 
tissues, cryosections were performed and every fifth section 
was stained with hematoxylin. Tumor cell areas were 
evaluated and marked by a pathologist. Tumor cells were 
removed from the unstained slides and further proceeded 
according to the manufactures protocol for isolation 
of DNA and RNA. Expression of mature miR-505-5p 
(MS00009849), miR‑520c‑3p (MS00007413) and U6‑
snRNA (RNUB6) (MS00033740) were determined by the 
miScript SYBR Green PCR Kit (Qiagen), and normalized 
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using the 2–ΔΔCt method relative to RNUB6. S100A4 and 
RPII expression was also quantified as described above 
and RPII served as normalization control. Primers are 
provided in Supplementary Table 5. Western blot analysis 
was performed using specific antibodies for S100A4 
(#Dako‑A5114) or β‑actin (#SIGMA‑A1978). 
Cell migration and invasion assay
These assays were performed as described 
previously by Ilm et al. [59]. Briefly, cells were seeded 
in 6-well plates and transfected with 50 nM control, 
miR-505-5p, miR-520c-3p or anti-miR-505-5p, miR-
520c‑3p (Thermo Fisher Scientific) using Lipofectamine 
RNAiMAX Reagent (Thermo Fisher Scientific) according 
to the manufacturer’s instructions. After 48 h of incubation 
the cells were seeded for migration and invasion assays. 
16 h later the migrated or invaded cells were quantified 
using Luminescent Cell Viability Assay (CellTiter-Glo®, 
Promega). These assays were performed three independent 
times, each in technical triplicates. 
5-Aza-2′-Deoxycytidine (5-aza) treatment 
of cells, bisulfite conversion of DNA and 
methylation and sequencing analysis
5′‑Aza treatment, bisulfite conversion and 
methylation analyses (PCR was performed using 
HotStarTaq Plus DNA Polymerase (#203605) from Qiagen, 
Germany) were performed as described previously [59]. 
CpG islands upstream of the TSS (Transcription start site) 
or pri-miR start site were determined with the CpG island 
searcher (http://www.uscnorris.com/cpgislands2/cpg.aspx), 
and PCR primers were designed using the Methprimer 
software (http://www.urogene.org/methprimer). The primer 
sequences are provided in Supplementary Table 6. 
A bisulfite‑sequencing PCR was done for the 152 bp 
long GC-rich region upstream of miR-520c. Converted 
DNA was amplified by PCR and the products were used 
for TOPO TA cloning kit (Invitrogen). Ten clones were 
sequenced from each cell line using T3 primer (sequence: 
AATTAACCCTCACTAAAGGG, LGC Biotech, Germany).
Combined bisulfite restriction analysis (COBRA)
COBRA was used to analyze the methylation status 
of the regulatory element of miR-520c. The primers were 
picked using MethPrimer via the CpG-island prediction 
function. Primer sequences are provided in Supplementary 
Table 7. The AmpliTaq Gold polymerase was used for the 
PCR. The PCR product was cleaned up using QIAquick 
PCR Purification kit following the standard protocol. The 
restriction enzyme BstUI was used for the analysis based 
on the recognition site. It cuts the sequence CGCG within 
the 152 bp PCR product at position 85, consequently 
creating one 67 bp and one 85 bp fragment. The digestion 
was performed in a thermocycler for 1 h at 60°C. A second 
control reaction was performed without enzyme for each 
sample. The whole sample was then loaded on a 3% 
agarose gel.
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism 5. The non‑parametric Mann‑Whitney‑U test was 
applied to calculate p-values for patients to compare 
two groups. The non-parametric Kruskal-Wallis test 
was applied for more than two groups. For all other data 
analysis, the comparison of two different groups was 
done by Student’s t-test. The Pearson model was used 
for correlation analysis. For all tests a p-value < 0.05 was 
considered as statistically significant. The whiskers of a 
box plot show 1.5 times the interquartile range according 
to the definition of Tukey.
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